Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Priti Lal, MD

Priti Lal, MD

faculty photo
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
6 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 2156626505
Education:
B.S. (Genetics)
Delhi University, Delhi, India, 1984.
MD
Maulana Azad Medical College, Delhi, India, 1990.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Description of Research Expertise

Application of high through-put technology to gain insights into the biology of human cancers, with special interest in GU cancers.

Description of Clinical Expertise

GU Pathology. Cardiovascular and renal transplantation pathology.

Selected Publications

Priti Lal, Kosj Yamoah, Amy Ziober, Amy Walker, Wenting Zhou, Elaine Spangler, Charnita Zeigler-Johnson, Michael Feldman, Timothy R. Rebbeck.: Racial Differences in the Distribution of Prostate Tumor Biomarkers and Treatment Failure: The SCORE Study. Clinical Cancer Research 2015.

Kosj Yamoah, Michael Hiroshi Johnson, Voleak Choeurng, Kasra Yousefi, Zaid Haddad, Robert Benjamin Den, Priti Lal, Michael D Feldman, Adam Dicker, Eric A. Klein, Elai Davicioni, Timothy R. Rebbeck, Edward M. Schaeffer: A novel biomarker signature which may predict aggressive disease in African-American men with prostate cancer. Journal of Clinical oncology 2015.

Kosj Yamoah, M.D., Ph.D.; Amy Walker, M.S.; Elaine Spangler, M.S.; Charnita M Zeigler-Johnson, M.D., Ph.D.; Bruce Malkowicz, M.D.; David I Lee, M.D.; Adam P Dicker, M.D., Ph.D.; Priti Lal, M.D. : African-American race is a predictor of seminal vesicle invasion following radical prostatectomy. Clinical Genitorurinary Cancer september 2014 Notes: Senior Author Paper.

Priti Lal, MD: Chapter 39: Prostate. Diagnostic molecular pathology. Diagnostic Molecular pathology, 2nd edition. Debra Leonard (eds.). Saunders Publications, 2015.

David J. Vaughn, MD,Wei-Ting Hwang, PhD,Priti Lal, MD,Mark Rosen, MD Maryann Gallagher, Peter J. O’Dwyer, MD: Phase II Trial of the CDK 4/6 Inhibitor Palbociclib in Patients with Retinoblastoma Protein Expressing Germ Cell Tumors. Cancer 2014.

Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas; : Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). ASCO 2014.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC: Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity. Cancer Discov 4(1): 53-60, Jan 2014 Notes: Co-Senior Author.

Priti Lal, MD: Applications of OCT 4 in Diagnostic immunohistochemistry Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition 2014.

Priti Lal, MD: Application of GATA 3 in diagnostic immunohistochemistry. Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition 2014.

Priti Lal, MD: Application of SALL4 in diagnostic immunohistochemistry. Leong's Manual of Diagnostic Antibodies for Immunohistology 3rd edition 2014.

back to top
Last updated: 07/01/2015
The Trustees of the University of Pennsylvania